Lutathera Meets Number one Endpoints in Development-Unfastened Survival for Gastroenteropancreatic Neuroendocrine Tumors
lutetium lu177 Dotatate (Lutathera; Novartis) met its number one endpoint within the segment 3 NETTER-2 trial (NCT03972488), together with vital enhancements in progression-free survival (PFS) for other people with improved…